Literature DB >> 15147334

Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.

M A Walter1, M Christ-Crain, B Eckard, C Schindler, E U Nitzsche, J Müller-Brand, B Müller.   

Abstract

BACKGROUND: High iodine uptake levels are widely accepted as a condition for successful treatment with radioiodine (RAI). However, the existing data are controversial and the correlation of pretherapeutic RAI uptake level and outcome of RAI therapy has not yet been quantified. The aim of this study was to analyze the influence of RAI uptake on the outcome after RAI treatment and to estimate uptake-dependent success rates.
MATERIALS AND METHODS: We retrospectively analyzed 229 patients (m = 53, f = 176; age 64 +/- 14 years) suffering from toxic adenoma, multinodular goitre or Graves' disease, respectively. Clinical status and T3, fT4 and TSH levels were assessed 3, 6, 12 and 18 months after treatment. Successful treatment was defined as loss of hyperthyroidism 18 months after radioiodine therapy. Logistic regression was used to assess the relation between the maximum iodine uptake and the rate of success and hypothyroidism, respectively, after RAI treatment.
RESULTS: Overall, patients presented with pretherapeutic RAI uptake values between 17% and 100%. Eighteen months after RAI treatment, an euthyroid state was achieved in 136 patients (60%), hypothyroidism occurred in 47 patients (20%) and 46 patients (20%) remained hyperthyroid. The patients with the lowest pretherapeutic RAI uptakes showed the highest success rates. The overall success rate significantly decreased from 92% at low RAI uptakes to 57% at high uptakes (P = 0.002). This effect was found in the patients suffering from multinodular goitre as well as in the patients with Graves' disease.
CONCLUSION: In contrast to the current opinion, our results provide evidence that the pretherapeutic iodine uptake level and post-therapeutic outcome are inversely correlated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147334     DOI: 10.1111/j.1365-2362.2004.01349.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  12 in total

1.  Serum 25-hydroxyvitamin D predict prognosis in radioiodine therapy of Graves' disease.

Authors:  X Li; G Wang; Z Lu; M Chen; J Tan; X Fang
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

2.  Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison.

Authors:  Martin A Walter; Mirjam Christ-Crain; Christian Schindler; Jan Müller-Brand; Beat Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-11       Impact factor: 9.236

3.  Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease.

Authors:  Se Hee Park; Sena Hwang; Seunghee Han; Dong Yeob Shin; Eun Jig Lee
Journal:  Int J Endocrinol       Date:  2017-12-05       Impact factor: 3.257

4.  Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.

Authors:  Hyun Joo Kim; Ji-In Bang; Ji-Young Kim; Jae Hoon Moon; Young So; Won Woo Lee
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

5.  Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.

Authors:  Rui-Ting Hu; De-Shan Liu; Bin Li
Journal:  BMC Endocr Disord       Date:  2020-05-29       Impact factor: 2.763

6.  Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.

Authors:  Yu-Zhuo Xing; Kun Zhang; Gang Jin
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

7.  Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults.

Authors:  Abigail U Canto; Paulette N Dominguez; Cecilia A Jimeno; Jerry M Obaldo; Ruben V Ogbac
Journal:  Endocrinol Metab (Seoul)       Date:  2016-03

8.  The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation.

Authors:  Muthiah Subramanian; Manu Kurian Baby; Krishna G Seshadri
Journal:  Endocr Connect       Date:  2016-01-15       Impact factor: 3.335

9.  Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I-: a retrospective study.

Authors:  Albert Stachura; Tomasz Gryn; Bernadetta Kałuża; Tadeusz Budlewski; Edward Franek
Journal:  BMC Endocr Disord       Date:  2020-06-01       Impact factor: 2.763

10.  Radioiodine Therapy of Graves' Disease and the Uptake Paradox.

Authors:  Sumeet Suresh Malapure; Anirban Mukherjee; Chandrasekar Bal
Journal:  Indian J Nucl Med       Date:  2019-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.